1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
D&D Pharmatech Co., Ltd.

D&D Pharmatech Co., Ltd.

KKRX:347850
40,750.00
KRW
-350.00
(-0.85%)
-541.15EPS
3.83TMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
34.77
- -
- -
42.4
18.94
523.45
282.01
99.8
62.97
Basic EPS, GAAP
-2,000.25
-475.25
-2,274.25
-2,120.75
-4,220.5
110.25
-705.78
-547
-494.63
Free Cash Flow per Basic Share
-233.98
-1,760.14
-1,853.93
-1,683.68
-1,668.83
-256.79
-547.92
-492.4
-570.79
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-427.65
620.27
4,334.76
3,166.79
226.29
1,118.24
1,658.58
1,825.96
3,075.71
Tangible Book Value per Share
-457.01
-3,470.66
651.12
-607.26
-827.99
122.95
840.82
1,128.81
2,372.83
Basic Weighted Avg Shares
10
13
28
32
32
36
41
43
44
Sales/Revenue/Turnover
348
- -
- -
1,364
611
18,677
11,437
4,298
2,750
Operating Margin (%)
-449.64
- -
- -
-5,547.71
-11,244.15
-72.21
-218.74
-790.97
-1,367.89
Depreciation Expense
324
7,859
11,343
11,901
13,739
4,428
5,527
5,531
5,662
Net Income, GAAP
-20,002
-6,359
-63,406
-68,224
-136,067
3,934
-28,623
-23,555
-21,605
Effective Tax Rate (%)
- -
- -
- -
- -
- -
23.76
- -
- -
- -
Profit Margin (%)
-5,752.2
- -
- -
-5,001.38
-22,285.31
21.06
-250.27
-548.09
-785.51
Working Capital
-31,898
-109,821
57,403
14,834
-21,568
12,078
28,680
45,569
178,356
LT Debt
- -
1,930
5,018
7,463
6,425
5,121
6,180
4,267
113,001
Total Equity
-17,840
26,961
181,307
138,328
18,519
55,218
69,569
78,979
134,094
Return on Invested Capital (%)
- -
- -
- -
- -
- -
-18.85
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
10.14
- -
- -
- -
Return on Common Equity (%)
- -
- -
-61.35
-43.6
-192.25
14.03
-49.03
-31.49
-20.24

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,978
2,066
2,093
LT Borrowings
- -
- -
109,558
LT Finance Leases
4,267
3,927
3,443
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
44
44
Market Capitalization
3,996,552
2,969,921
3,832,863

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
50,988
45,894
185,161
Cash, Cash Equivalents & STI
32,884
24,573
152,258
Accounts Receivable, Net
- -
- -
166
Inventories
- -
- -
- -
Total Current Liabilities
5,419
5,726
6,806
Payables & Accruals
- -
- -
- -
ST Debt
1,978
2,066
2,093
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.47%
13.53%
Free Cash Flow
- -
11.82%
-4.58%
Net Income, GAAP
- -
-168.23%
-17.71%
Sales/Revenue/Turnover
- -
- -
-62.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,102
2,317
1,940
5,055
11,437
2025
1,413
925
969
990
4,298
2026
129
662
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-147.75
-142.25
-189.75
-222.21
-705.78
2025
-58
-57.25
-130.28
41.53
-547
2026
-217.71
-187
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Seul-Ki Lee
Full Time Employees
22
Sector
Health technology
Industry
Pharmaceuticals: major
Address
27, Geumto-ro 80beon-gil, Seongnam-si GY South Korea 13453
IPO Date
May 2, 2024
Website
ddpharmatech.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
D&D Pharmatech Inc. (347850.KQ), a clinical-stage biotechnology company founded in 2014 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, develops innovative therapeutics for metabolic diseases, neurodegenerative disorders, fibrotic conditions, and oncology; its pipeline features GLP-1 receptor agonists including NLY01-PD, NLY01-AD, and NLY01-D in Phase II trials for Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively, alongside P4M01, which completed Phase IIa for periodontal disease; Phase I candidates encompass DD01 for obesity/diabetes/NASH, TLY012 for NASH-liver fibrosis/chronic pancreatitis/systemic sclerosis, and PMI03 through PMI06 targeting PD/AD/neuroinflammation/ALS/depression/oncology/immuno-oncology; preclinical programs include NLY03 for stroke/PD, DD03 for obesity/NASH, and others like NLY02, NLY12, and PMI21/PMI07 for diabetes/obesity/prostate cancer/fibrosis/oncology. The company operates primarily in South Korea and the United States through subsidiaries such as Neuraly Inc., Precision Molecular Inc., Theraly Fibrosis Inc., P4Microbiome, and Valted Seq Inc., serving healthcare markets focused on high-unmet-need areas like neurodegeneration and metabolic syndromes via advanced platforms including HiF-Seq for big data analysis, Oralink oral peptide delivery, and long-acting injectables. Recent developments include a June 2025 agreement to acquire an additional 25% stake in Valted Seq Inc. for $10.8 million, boosting ownership to 93.75% to enhance neurodegenerative research; a $51 million Series C financing round in July 2025 led by Praxis Capital Partners to advance clinical candidates; and strategic licensing of its Oralink platform to Metsera in 2023-2024 (valued up to $700 million), positioning for potential benefits from Pfizer's reported acquisition interest in Metsera as of September 2025.